The 4D randomized clinical trial demonstrates that dexmedetomidine significantly reduces agitation duration and improves clinical outcomes in non-intubated ICU patients with hyperactive delirium, providing a safe and effective alternative to standard care without increasing the need for mechanical ventilation.